Prosecution Insights
Last updated: November 04, 2026
Application No. 18/999,576

Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer

Non-Final OA §103§DOUBLEPATENT
Filed
Dec 23, 2024
Priority
Jun 13, 2018 — provisional 62/684,681 +4 more
Examiner
JACKSON, SHAWQUIA
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Unity Biotechnology, Inc.
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
5m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
1439 granted / 1843 resolved
+18.1% vs TC avg
Minimal -4% lift
Without
With
+-3.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
46 currently pending
Career history
1891
Total Applications
across all art units

Statute-Specific Performance

§101
2.6%
-37.4% vs TC avg
§103
15.0%
-25.0% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
50.6%
+10.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1843 resolved cases

Office Action

§103 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 21-24 are currently pending in the instant application. Applicants have canceled claims 1-20 and added new claims 21-24 in an amendment filed on February 27, 2025. Claims 21-24 are rejected in this Office Action. I. Priority The instant application is a CON of 17/338,368, filed on June 3, 2021 PAT 12,221,433 which is a CON of 16/888,197, filed on May 29, 2020 ABN which is a CON of 16/446,360, filed on June 19, 2019 PAT 10,717,722 which is a CON of PCT/US2019/037067, filed on June 13, 2019 which claims benefit of US Provisional Application 62/684,681, filed on June 13, 2018. II. Information Disclosure Statement The information disclosure statement (IDS) submitted on February 27, 2025 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner. III. Rejections Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Claims 21-24 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 1 of U.S. Patent No. 12,221,433. Although the conflicting claims are not identical, they are not patentably distinct from each other because: Applicants claim PNG media_image1.png 608 806 media_image1.png Greyscale Determining the Scope and Content of the Issued Patent Claim 1 of the issued patent claims PNG media_image2.png 280 312 media_image2.png Greyscale PNG media_image3.png 267 289 media_image3.png Greyscale Ascertaining the Differences Between the Instant Application and the Issued Patent The instant application claims a kit comprising the same compound that the issued patent’s claim is drawn to. Finding Prima Facie Obviousness The scope of the compound in the patented claim 1 and the scope of the claims 21-24 of the instant application overlap and include patented subject matter in the instant claims. Therefore, one of ordinary skill in the art would be motivated to prepare and claim the scope of the compounds in the issued patent again in the instant application since the scope already patented falls within the full scope of the instant claims 21-24. As a result, the claims are rejected under obviousness-type double patenting. Claims 21-24 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 10,717,722. Although the conflicting claims are not identical, they are not patentably distinct from each other because: Applicants claim PNG media_image1.png 608 806 media_image1.png Greyscale Determining the Scope and Content of the Issued Patent Claim 1 of the issued patent claims PNG media_image4.png 536 277 media_image4.png Greyscale PNG media_image5.png 760 541 media_image5.png Greyscale PNG media_image6.png 716 412 media_image6.png Greyscale Ascertaining the Differences Between the Instant Application and the Issued Patent The instant application claims a kit comprising the same compound that the issued patent’s claim is drawn to in claim 9. Finding Prima Facie Obviousness The scope of the compound in the patented claims 1-9 and the scope of the claims 21-24 of the instant application overlap and include patented subject matter in the instant claims. Therefore, one of ordinary skill in the art would be motivated to prepare and claim the scope of the compounds in the issued patent again in the instant application since the scope already patented falls within the full scope of the instant claims 21-24. As a result, the claims are rejected under obviousness-type double patenting. 35 USC § 103 - OBVIOUSNESS REJECTION The following is a quotation of 35 U.S.C. § 103(a) that forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. Graham v. John Deere Co. set forth the factual inquiries necessary to determine obviousness under 35 U.S.C. §103(a). See Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966). Specifically, the analysis must employ the following factual inquiries: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 21-24 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Wang, et al. (US 2012/0189539 A1) in view of Abu-Jaish, et al. and Wang, et al. (US 2014/0199234 A1). Applicants claim PNG media_image1.png 608 806 media_image1.png Greyscale . The Scope and Content of the Prior Art (MPEP §2141.01) Wang, et al. (US 2012/0189539 A1) teaches BCL-2/BCL-XL inhibitors. The invention is represented by the general formula: PNG media_image7.png 326 148 media_image7.png Greyscale PNG media_image8.png 332 305 media_image8.png Greyscale PNG media_image9.png 596 358 media_image9.png Greyscale (see page 8) and further teaches the species PNG media_image10.png 256 464 media_image10.png Greyscale (See compound 205, page 95). Abu-Jaish, et al. teaches prodrugs and more specifically the use of a phosphate prodrug which is linked to a free hydroxyl group and increases the aqueous solubility of the compound (see page 14). Wang, et al. (US 2014/0199234 A1) which teaches BCL-2/BCL-XL inhibitors with similar structures that have a hydroxyl group phosphorylated such as the compound PNG media_image11.png 302 386 media_image11.png Greyscale (see compound 3, page 9) which maintains the BCL-2/BCL-XL inhibitory activity. The Difference Between the Prior Art and the Claims (MPEP §2141.02) The difference between the prior art of Wang, et al. (US 2012/0189539 A1) and the instant compounds is that the instant compound has the PNG media_image12.png 52 98 media_image12.png Greyscale group phosphorylated as a prodrug whereas the prior art’s compound does not. The other prior art references teaches the use of a phosphate group on free hydroxyl groups as a prodrug. Prima Facie Obviousness-The Rational and Motivation (MPEP §2142-2413) In In re Thornberg, 103 F. 2s 387 (CCPA 1966), it was well established that in determining obviousness, a combination of references need not result precisely in applicant’s structure. Rather, the question is whether the invention would have been obvious in light of the combination. The prior art teaches the compound PNG media_image10.png 256 464 media_image10.png Greyscale which is similar to the claimed compound PNG media_image13.png 205 471 media_image13.png Greyscale which is a prodrug of the prior art’s compound. It is well known in the art to prepare phosphate prodrugs of well-known compounds for the purpose of increasing the water solubility of the compound as taught in the Abu-Jaish, et al. reference. The second Wang, et al .reference teaches compounds with similar structures and the same utility that have a phosphate group attached the same group as seen in the instant compound and the activity was maintained. Therefore, it would be within one of ordinary skill in the art to prepare a phosphate prodrug of the known compound PNG media_image10.png 256 464 media_image10.png Greyscale as a BCL-2 inhibitor having increased aqueous solubility with a reasonable expectation for success. Phosphate prodrugs are well known in the art and would be obvious to prepare. Therefore, it would have been prima facie obvious to one having ordinary skill in the art at the time the invention was made to prepare a phosphate prodrug of PNG media_image10.png 256 464 media_image10.png Greyscale based on the teachings of the preferred embodiments in the prior art references. A strong prima facie obviousness has been established. IV. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is 571-272-9043. The examiner can normally be reached on 7:00 AM-3:30PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Adam Milligan can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /SHAWQUIA JACKSON/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Dec 23, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774305
NOVEL CYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THE USE OF SAID CYCLIC COMPOUNDS IN COSMETIC PREPARATIONS
3y 5m to grant Granted Oct 27, 2026
Patent 12767649
PROCESS FOR THE SYNTHESIS OF 5-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)FURAN-2-CARBALDEHYDE AND OF NITRONES FROM 5-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)FURAN-2-CARBALDEHYDE
2y 4m to grant Granted Oct 20, 2026
Patent 12759978
Novel Psilocin Analog Compositions And Methods of Synthesizing The Same
3y 5m to grant Granted Oct 13, 2026
Patent 12758559
RXFP1 AGONISTS
2y 6m to grant Granted Oct 13, 2026
Patent 12753183
1,5-DISUBSTITUTED 1,2,3-TRIAZOLES ARE INHIBITORS OF RAC/CDC42 GTPASES
2y 7m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
75%
With Interview (-3.5%)
2y 3m (~5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1843 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month